|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Nov 24 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Abbott Drops a $23B Mega move to Dominate Cancer Diagnostics
|
|
| | J&J Strikes Big with Halda Therapeutics in a Game-Changing Oncology Play
|
|
| | GE HealthCare Supercharges Its AI and Cloud Footprint with Intelerad Buyout
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Abbott Sets the Pace in Cancer Diagnostics: The $23 Billion Exact Sciences Megadeal
|
| |
|
| |
Abbott Bets Big on Cancer Diagnostics with Exact Sciences Acquisition
|
| |
In a headline-grabbing move, Abbott has sealed a $23 billion deal to acquire Exact Sciences—marking not only the biggest healthcare acquisition of the year but also a transformative leap into the future of cancer screening and precision diagnostics. The agreement—at $105 per share, with a total equity value of $21 billion and absorption of $1.8 billion in net debt—puts Abbott in control of some of the most influential cancer testing platforms on the market, with closing expected in Q2 2026 pending regulatory and shareholder approval.
|
| |
Instant diagnostic muscle: Abbott takes over Exact Sciences, instantly unlocking four market-shaping cancer tests:
|
| |
| • | Cologuard: an easy, at-home screen for colorectal cancer.
|
|
| • | Oncotype DX: the gold standard for personalizing breast cancer care.
|
|
| • | Oncodetect: advanced MRD monitoring for cancer relapse.
|
|
| • | Cancerguard: a cutting-edge blood test for multi-cancer early detection.
|
|
| |
Abbott now sits at the core of cancer care—from screening to smart treatment decisions—all powered by high-growth precision diagnostics.
|
| |
A New Era of Diagnostic Leadership for Abbott
|
| |
This acquisition propels Abbott to the forefront of cancer diagnostics, instantly expanding its presence in the rapidly growing $60B U.S. cancer screening and oncology market. Integrating Exact Sciences elevates Abbott’s diagnostics revenue to more than $12B annually, with high-teens organic growth projected. More importantly, the deal positions Abbott as one of the few companies capable of delivering both routine and advanced precision testing across the entire cancer care continuum—driving innovation, broadening access, and raising the global standard for early detection and informed treatment decisions.
|
| |
|
| |
| | Oncology Rules the Trends: Targeted Therapies for Solid Tumors
|
|
|
|
|
| |
J&J Snaps Up Halda Therapeutics in a Bold Oncology Play
|
| |
|
| |
Johnson & Johnson Takes a Bold Step in Oncology with Halda Therapeutics Acquisition
|
| |
Biotech deal-making continues to reshape the next frontier in cancer care—this time with a decisive move from Johnson & Johnson. The company has announced a definitive agreement to acquire Halda Therapeutics for $3.05 billion in cash, adding a wave of first-in-class science to its pipeline and affirming a long-term commitment to innovative cancer therapy.
|
| |
Decoding the Deal: The Science at Its Core
|
| |
| • | J&J acquires Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, a next-gen technology aimed at delivering oral targeted therapies for solid tumors spanning multiple cancers, including breast and lung.
|
|
| • | The deal adds a pipeline of early- and mid-stage oncology candidates, equipped with novel mechanisms of action for diverse patient groups.
|
|
| • | A standout candidate is HLD-0915—a bifunctional, oral therapy in Phase I/II trials for prostate cancer, designed to form a unique “hold and kill” ternary complex within cancer cells. HLD-0915 is engineered to drive down tumor burden, including in genetically complex, treatment-resistant patients.
|
|
| |
The Smart Bet with Big Implications
|
| |
| • | J&J significantly expands its precision oncology arsenal with a platform that tackles major hurdles like treatment resistance and tumor diversity.
|
|
| • | The RIPTAC approach not only builds promising science but is now moving decisively into clinical development—heralding a new era for hard-to-treat cancers.
|
|
| • | With the acquisition expected to close in the coming months, J&J is making a clear statement: it’s committed to accelerating transformative, patient-centric cancer care through disruptive targeted therapies
|
|
| |
|
| |
|
| |
| | Preparing for Future: The Ai Wave in Life Science is Already Here
|
|
|
|
|
| |
A Major AI Leap: GE HealthCare Acquires Intelerad
|
| |
|
| |
GE HealthCare Strengthens Cloud & AI Reach with Intelerad Acquisition
|
| |
GE HealthCare has announced a $2.3 billion all-cash acquisition of Intelerad, reflecting a major move to accelerate its strategy in cloud-based and AI-powered healthcare technology. The deal is slated to close in the first half of 2026, pending regulatory approvals.
|
| |
What GE HealthCare Gains
|
| |
| • | By acquiring Intelerad, GE HealthCare adds a suite of highly advanced, cloud-native radiology and cardiology imaging platforms to its portfolio.
|
|
| • | These enterprise workflow solutions are relied upon by more than 1,500 health organizations globally, showing their strong market adoption and proven impact in real-world healthcare settings.
|
|
| |
Impact on Imaging and Collaboration
|
| |
| • | Integration of Intelerad’s technology will help GE HealthCare streamline medical imaging processes—driving faster diagnostics, improving collaboration among care teams, and boosting operational efficiency, especially for outpatient and teleradiology networks.
|
|
| • | The combined platform supports scalable and connected imaging solutions, helping health systems adapt as patient volumes and complexity increase.
|
|
| |
Broader Strategic Advantages
|
| |
| • | This move extends GE HealthCare’s leadership from the hospital into outpatient and community care environments, broadening the reach of its AI-enabled imaging tools for care teams worldwide.
|
|
| |
Ultimately, the acquisition underscores GE HealthCare’s focus on digital innovation and delivering smarter healthcare technologies that elevate clinical outcomes for both patients and providers.
|
| |
|
| |
AI Meets Brain Health: Valo and Merck KGaA Ink $3B+ Mega Deal
|
| |
|
| |
Valo Health and Merck KGaA Forge $3B+ AI-Driven Deal in Neurodegenerative Disease
|
| |
Valo Health has inked a global partnership with Merck KGaA, uniting advanced AI with world-class drug development to break new ground in Parkinson’s and neurodegenerative disease research.
|
| |
Financial Terms and Scope
|
| |
Valo Health stands to gain more than $3 billion through:
|
| |
| • | Upfront payments as a starting investment.
|
|
| • | Additional milestone payments tied to research and clinical achievements.
|
|
| • | Ongoing royalties from successful products.
|
|
| • | Dedicated R&D funding to drive project innovation.
|
|
| |
Platform Technology and Process
|
| |
| • | The collaboration is powered by Valo's human causal biology platform, which analyzes over 17 million patient records and biobank samples with advanced AI to spot new disease patterns and targets.
|
|
| • | Valo’s closed-loop discovery platform further accelerates the development of small molecule therapeutics—aiming to shorten drug development timelines and boost confidence in emerging targets by linking real-world human data directly to early-stage experiments.
|
|
| |
By pairing Merck KGaA’s expertise in neurology with Valo’s computational muscle, the alliance aims to open up therapeutic opportunities in one of medicine’s toughest areas—where new options for Parkinson’s and similar disorders remain urgently needed.
|
| |
|
| |
|
| |
| | Partnering Wave: Deals That Redraw Therapeutic Boundaries
|
|
|
|
|
| |
This week’s deals read like a map of where capital and conviction are flowing: Subcutaneous Innovation, and Myeloid Cell Engagers in Oncology.
|
| |
1. SC Breakthrough on the Horizon
|
| |
Merus Partners with Halozyme for Petosemtamab
|
| |
|
| |
Merus Taps Halozyme to Fast-Track Subcutaneous Innovation for Petosemtamab
|
| |
Biotech partnerships are speeding up not just how quickly, but how comfortably, patients can access cutting-edge therapies. Merus has struck a worldwide, non-exclusive deal with Halozyme Therapeutics to craft a subcutaneous (SC) version of its next-generation antibody petosemtamab, powered by Halozyme’s Enhanze technology—a move set to change the infusion game for cancer patients.
|
| |
Halozyme gets immediate financial recognition: an upfront payment, plus additional milestones tied to commercial and sales benchmarks, and low- to mid-single-digit royalties on future SC petosemtamab sales. Specific amounts remain private, but what’s public is the momentum for more patient-centric drug delivery.
|
| |
Why is this big?
|
| |
Enhanze—featuring the rHuPH20 enzyme—enables rapid, convenient SC dosing of biologic therapies. That translates to
|
| |
|
|
| • | A more patient-friendly treatment option, as the industry continues its push for flexible oncology care
|
|
| |
Subcutaneous innovation has moved from “nice to have” to “must win” across biopharma—and Merus just made its bet.
|
| |
2. Myeloid Cell Engagers in Oncology
|
| |
GSK Strikes Big with LTZ in the Race for Myeloid Cell Engagers
|
| |
GSK Taps LTZ Therapeutics to Lead the Charge on Myeloid Cell Engagers in Oncology
|
| |
Big collaborations are shaping the future of cancer care—and this one is a game-changer. GSK has entered a high-impact strategic research alliance with LTZ Therapeutics, aiming to fast-track innovative myeloid cell engagers (MCEs) by leveraging LTZ’s advanced immune-engager platform.
|
| |
The Agreement, Unpacked
|
| |
| • | GSK secures an exclusive option to license global rights for up to four myeloid cell engager (MCE) therapies.
|
|
| • | LTZ Therapeutics receives a $50 million upfront payment.
|
|
| • | LTZ is eligible for further preclinical, clinical, regulatory, and commercial milestone payments.
|
|
| • | LTZ will also earn tiered royalties on future global net sales of any commercialized MCE therapies.
|
|
| |
The Big Differentiator
|
| |
| • | Targets both hematologic cancers and solid tumors—expanding the reach of myeloid cell engager technology.
|
|
| • | Combines LTZ’s innovative platform with GSK’s development expertise for accelerated progress in immuno-oncology.
|
|
| • | Highlights immune-engager therapies as a central force in next-gen cancer treatment strategies, not just an emerging niche.
|
|
| |
Immune-engager technologies are no longer a niche—they’re at the center of next-gen cancer strategies, and GSK just placed its bet.
|
| |
|
| |
|
| |
| | The Data Pulse: Phase III & Early-Stage Trials to Watch
|
|
|
|
|
| |
This week’s trials signal exactly where regulators and payers are turning next and where the next wave of label expansions and competitive threats is likely to hit.
|
| |
1.Oral SERD Sets Benchmark
|
| |
Highlights from the P-III lidERA Breast Cancer Study by Genentech
|
| |
|
| |
Genentech has shared pivotal Phase III data from the lidERA trial, evaluating daily oral giredestrant against standard endocrine therapy in over 4,100 people with medium- or high-risk Stage I–III ER+, HER2- breast cancer.
|
| |
Key Trial Outcomes
|
| |
| • | The study met its primary endpoint, delivering a statistically robust, clinically meaningful boost in invasive disease-free survival compared to standard endocrine therapy.
|
|
| • | Overall survival results favor giredestrant but are not yet mature.
|
|
| • | Detailed analyses are underway, with full results set for upcoming medical meetings and global regulatory submission.
|
|
| |
Significance
These results mark giredestrant as the first oral SERD to deliver a significant adjuvant benefit in early, hormone receptor–positive breast cancer. Genentech’s trial signals a major shift in endocrine therapy—potentially reshaping standards and improving care for thousands each year.
|
| |
2.Pulmonary Hypertension
|
| |
Insights from the P-II Cadence Study by Merck
|
| |
Merck has unveiled promising topline results from the Phase II CADENCE study, testing Winrevair (sotatercept-csrk) at 0.3 mg/kg and 0.7 mg/kg against placebo in 164 patients with combined post-capillary and pre-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF)—a group with few real therapeutic options.
|
| |
Key Findings
|
| |
| • | Primary endpoint achieved: Significant reduction in pulmonary vascular resistance at 24 weeks, showing Winrevair’s ability to improve blood flow dynamics in these complex patients.
|
|
| • | Clinical relevance: Highlights Winrevair’s potential to slow disease progression and offer meaningful benefits in a high-need population.
|
|
| • | Safety: Demonstrated a favorable safety and tolerability profile in line with previous studies, clearing the path for larger trials.
|
|
| |
With CADENCE, Merck is building momentum for Winrevair as a game-changing candidate in cardiovascular medicine, aiming to transform care for patients with limited options where the unmet need remains substantial
|
| |
3.Weight Loss
|
| |
Highlights from the P-III GLORY-2 Study by Innovent Biologics
|
| |
|
| |
Innovent Biologics Phase III GLORY-2 trial has delivered striking results for mazdutide (9 mg), evaluated alongside lifestyle intervention in 462 Chinese adults with obesity (BMI ≥30 kg/m²), including a subset of patients with Type 2 diabetes.
|
| |
Key Efficacy Outcomes
|
| |
| • | Primary endpoint met: Continuous, sustained weight loss through 60 weeks—no plateau observed.
|
|
| • | Mazdutide group: 18.55% mean weight reduction vs 3.02% with placebo.
|
|
| • | 44% achieved ≥20% weight loss, compared to 2.6% receiving placebo.
|
|
| |
Significance
|
| |
With robust impacts on weight, cardiometabolic risk, and liver health, GLORY-2 positions mazdutide as a potentially transformative therapy for obesity—one that could reshape treatment standards in China and set new expectations globally.
|
| |
4.Next-Gen HIV Care
|
| |
Topline Data from the P-III MK-8591A-053 Study by Merck
|
| |
Merck has reported pivotal results from the Phase III MK-8591A-053 trial, comparing a once-daily, two-drug oral regimen of doravirine (100 mg) and islatravir (0.25 mg) to the established triple therapy BIC/FTC/TAF in 537 treatment-naïve adults living with HIV-1.
|
| |
Efficacy Evolution
|
| |
| • | Primary endpoint achieved: DOR/ISL proved non-inferior to BIC/FTC/TAF for viral suppression (HIV-1 RNA <50 copies/mL at Week 48), cementing the new combo as a next-generation alternative for initial therapy
|
|
| |
Safety Confidence
|
| |
| • | The regimen met its primary safety objective, supporting a streamlined, well-tolerated profile and simpler, once-daily dosing.
|
|
| |
What’s Next
With its favorable efficacy and safety, Merck’s
DOR/ISL regimen may offer a convenient, dual-drug treatment option poised to improve quality of life for people with HIV—further reinforcing the company’s innovation in antiviral therapeutics.
|
| |
|
| |
|
| |
|
| |
| | Regulatory Wins: From Immunology to Dermatology
|
|
|
|
|
| |
The past week delivered a surge of major regulatory milestones across immunology, oncology, neurology, dermatology, and rare diseases—signaling accelerated momentum for next-generation therapeutics worldwide. Here’s a breakdown of the most pivotal updates shaping the industry right now.
|
| |
|
| |
Key milestones:
|
| |
| 1. | Sanofi’s Teizeild (teplizumab) secured a positive opinion from the CHMP as a therapy to delay the progression of Type 1 diabetes, marking a critical advance in early-stage intervention for at-risk patients.
|
|
| 2. | Ionis and Otsuka’s Dawnzera (donidalorsen) earned a CHMP recommendation as a prophylactic treatment for hereditary angioedema, offering a new preventive option for patients facing unpredictable and potentially life-threatening attacks.
|
|
| 3. | Incyte received a positive CHMP opinion for Minjuvi in combination therapy for relapsed or refractory follicular lymphoma, supporting a potential new option for a population with limited treatment durability.
|
|
| 4. | Arcutis reported the FDA acceptance of its sNDA for Zoryve (roflumilast) to treat plaque psoriasis in children, expanding access to a non-steroidal topical option with growing clinical traction.
|
|
| 5. | Celcuity announced that the FDA has accepted the NDA for gedatolisib, a PI3K/mTOR inhibitor targeting advanced breast cancer, moving the therapy closer to potential approval.
|
|
| 6. | Genmab and AbbVie secured FDA approval for Epkinly to treat relapsed or refractory follicular lymphoma, further expanding the bispecific antibody’s footprint across hematologic cancers.
|
|
| 7. | Arrowhead Pharmaceuticals gained FDA approval for Redemplo (plozasiran) to treat familial chylomicronemia syndrome, marking a significant win for patients with this ultra-rare, burdensome lipid disorder.
|
|
| 8. | Insmed reported EC approval of Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis, bringing the first approved therapy to a neglected respiratory condition.
|
|
| 9. | The EC granted approval to Bayer’s Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms, giving women a non-hormonal therapeutic alternative backed by strong clinical data.
|
|
| 10. | Merck’s Keytruda (subcutaneous formulation) achieved EC approval across 33 solid tumor indications, opening the door to faster, more convenient administration of one of oncology’s most widely used immunotherapies.
|
|
| 11. | AstraZeneca reported FDA approval of Koselugo (selumetinib) for patients with neurofibromatosis type 1, expanding an important targeted option for this rare genetic disorder.
|
|
| 12. | Bayer secured accelerated FDA approval for Hyrnuo (sevabertinib) to treat HER2-mutant non-small cell lung cancer, adding a new precision therapy to a rapidly evolving area of lung cancer care.
|
|
| |
The pattern:
|
| |
| • | Across the US, EU, and beyond, this week’s decisions underscore a clear trend: regulators are moving rapidly on innovative therapies that address high-need, high-impact diseases.
|
|
| • | These developments collectively signal a powerful shift toward earlier intervention, more targeted mechanisms, and expanded patient access—setting the stage for a dynamic year ahead in biopharma innovation
|
|
| |
|
| |
|
| |
| | MedTech: Regulatory Tailwind for Diagnostics & Devices
|
|
|
|
|
| |
MedTech on the Move: This Week’s Key Regulatory Greenlights
|
| |
A strong regulatory tailwind is pushing MedTech into a sharper, precision-first future:
|
| |
| 1. | A meaningful step forward for surgical precision, Zimmer Biomet’s ROSA Knee with OptimiZe has received 510(k) clearance from the FDA, reinforcing the company’s commitment to advancing personalized and data-driven orthopaedic care
|
|
| |
|
| |
| 1. | In a win for precision oncology, Thermo Fisher Scientific’s Oncomine Dx Target Test has been approved by the FDA as a companion diagnostic, further enabling targeted treatment decisions and expanding access to high-value genomic insights.
|
|
| |
The takeaway: Together, these milestones underscore the accelerating pace of innovation in MedTech—where smarter tools, data-driven insights, and precision diagnostics continue to reshape patient care and clinical decision-making.
|
| |
|
| |
|
| |
| | Biosimilar Breakthroughs: New Launches & Landmark Approvals
|
|
|
|
|
| |
Unlocking Biosimilars Approvals: Momentum Builds Across Markets
|
| |
Regulatory agencies in the US and EU continue to open doors for high value biosimilars, reinforcing global efforts to expand access, reduce treatment costs, and enhance therapeutic choice. This week delivered three meaningful wins for manufacturers advancing the next wave of biologic competition
|
| |
1. EC Clears New Presentation of Celltrion’s Omlyclo (Biosimilar to Xolair)
|
| |
The European Commission has approved an additional presentation of Celltrion’s Omlyclo, strengthening its position as a biosimilar alternative to Xolair. This expansion enhances flexibility for clinicians and patients while supporting broader adoption across allergic and immunologic conditions.
|
| |
2. FDA Approves Henlius and Organon’s Poherdy (Biosimilar to Perjeta)
|
| |
In a key milestone for US biosimilar expansion, Poherdy has secured U.S. FDA approval as a biosimilar to Perjeta. This marks an important addition to treatment options in HER2-positive breast cancer, offering a more affordable pathway to a cornerstone biologic therapy.
|
| |
|
| |
3. EC Grants Approval to Alvotech & Advanz Pharma’s Gobivaz (Biosimilar to Simponi)
|
| |
Gobivaz has received EC approval for multiple chronic inflammatory diseases, from rheumatoid arthritis to ulcerative colitis. This decision brings a new competitive entrant to the immunology landscape—one with the potential to meaningfully improve patient access across Europe.
|
| |
4. Sandoz Rolls Out Tyruko, a Biosimilar Set to Reshape MS & Crohn’s Care
|
| |
Sandoz has officially launched Tyruko, the first and only biosimilar to Biogen’s blockbuster therapy Tysabri (natalizumab)—bringing a major new option to patients with relapsing forms of multiple sclerosis (MS) and moderate to severe active Crohn’s disease.
|
| |
|
| |
| | Platforms That Don’t Fit Neatly in a Box: Animal Health
|
|
|
|
|
| |
Boehringer Ingelheim Scores CVMP Backing for Dual Vaccine Strategy Against Avian Influenza
|
| |
In a major step forward for global poultry health, Boehringer Ingelheim has received a positive opinion from the EMA’s Committee for Medicinal Products for Veterinary Use (CVMP) for two next-generation vaccines targeting H5 avian influenza: Vaxxitek HVT+IBD+H5 and Vaxxinact H5.
|
| |
|
| |
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
This week underscored one thing: biopharma isn’t slowing down—it’s doubling down.
|
| |
From fast-track approvals to next-gen vaccines and biosimilar momentum, innovation moved in every direction. But the headline that truly reshaped the landscape was the $23B acquisition—a decisive move that signals how fiercely companies are competing to secure future-defining pipelines.
|
| |
It wasn’t just a deal. It was a statement.
|
| |
A statement that scale, speed, and scientific depth will define the next era of healthcare—and the players ready to invest boldly today will set the pace tomorrow.
|
| |
If this newsletter helped you think sharper about your pipeline, competitors, or roadmap, don’t let it be a one-off.
|
| |
| • | Subscribe to PharmaShots Weekly to get this in your inbox every Monday at 8 AM EST.
|
|
| • | Forward this email to one teammate in R&D, CI, or strategy who hates wasting time on noisy newsfeeds.
|
|
| • | Share a snippet on LinkedIn and tag PharmaShots so we can amplify your take.
|
|
| • | Biopharma doesn’t slow down. Your intelligence feed shouldn’t either.
|
|
| |
Stay curious. Stay informed. Stay ahead with PharmaShots Weekly. See you next Monday at 8 AM EST.
|
| |
| | Questions?
Reach out to us [email protected] for any comments, questions, partnership and media inquiry.
|
|
|
|
|
| |
|
0 comments